Abstract
Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.
| Original language | English |
|---|---|
| Pages (from-to) | 98-102 |
| Number of pages | 5 |
| Journal | Brain Tumor Pathology |
| Volume | 34 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2017 Apr 1 |
Fingerprint
Keywords
- Bevacizumab
- Craniotomy
- Glioblastoma
- Thrombosed microvessels
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
- Cancer Research
Cite this
A case of glioblastoma resected immediately after administering bevacizumab : consideration on histopathological findings and safety of surgery. / Tokuda, Yukina; Tamura, Ryota; Ohara, Kentaro; Yoshida, Kazunari; Sasaki, Hikaru.
In: Brain Tumor Pathology, Vol. 34, No. 2, 01.04.2017, p. 98-102.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A case of glioblastoma resected immediately after administering bevacizumab
T2 - consideration on histopathological findings and safety of surgery
AU - Tokuda, Yukina
AU - Tamura, Ryota
AU - Ohara, Kentaro
AU - Yoshida, Kazunari
AU - Sasaki, Hikaru
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.
AB - Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.
KW - Bevacizumab
KW - Craniotomy
KW - Glioblastoma
KW - Thrombosed microvessels
UR - http://www.scopus.com/inward/record.url?scp=85018468796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018468796&partnerID=8YFLogxK
U2 - 10.1007/s10014-017-0285-9
DO - 10.1007/s10014-017-0285-9
M3 - Article
C2 - 28429093
AN - SCOPUS:85018468796
VL - 34
SP - 98
EP - 102
JO - Brain Tumor Pathology
JF - Brain Tumor Pathology
SN - 1433-7398
IS - 2
ER -